Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Replicel Life Sciences Inc (REPCF)

Replicel Life Sciences Inc (REPCF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing AccessWire - Tue Jul 26, 2022

This press release replaces the press release disseminated July 26, 2022 at 06:00 EDT. The press release contained the wrong image - one intended for a future press release. The corrected press release...

REPCF : 0.0002 (-90.48%)
RP.VN : 0.010 (unch)
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing AccessWire - Tue Jul 26, 2022

Independent dermatology research experts at Monasterium Laboratory GmbH tested, analyzed and validated various injection parameters using donated human tissue

REPCF : 0.0002 (-90.48%)
RP.VN : 0.010 (unch)
RepliCel Announces Material Patent Milestones AccessWire - Mon Jan 10, 2022

New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets VANCOUVER, BC / ACCESSWIRE / January 10, 2022 / RepliCel Life Sciences Inc....

REPCF : 0.0002 (-90.48%)
RP.VN : 0.010 (unch)
RepliCel Closed Final Tranche of Strategic Investment Commitment AccessWire - Tue Dec 21, 2021

VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics...

REPCF : 0.0002 (-90.48%)
RP.VN : 0.010 (unch)
RepliCel Terminates License Agreement with Shiseido AccessWire - Tue Dec 21, 2021

VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics...

REPCF : 0.0002 (-90.48%)
RP.VN : 0.010 (unch)
RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing AccessWire - Thu Nov 11, 2021

Independent dermatology research experts at Monasterium Laboratory GmbH will test, analyze and validate various injection parameters using donated human tissue VANCOUVER, BC / ACCESSWIRE / November 11,...

RP : 88.72 (+0.08%)
REPCF : 0.0002 (-90.48%)
RP.VN : 0.010 (unch)
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team AccessWire - Tue Nov 9, 2021

RepliCel's CRO and regulatory advisors now begin preparing Japanese-language documentation to support study clearance VANCOUVER, BC / ACCESSWIRE / November 9, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2)...

REPCF : 0.0002 (-90.48%)
RP.VN : 0.010 (unch)
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line AccessWire - Thu Oct 28, 2021

Trademark registrations kickoff pre-commercial planning VANCOUVER, BC / ACCESSWIRE / October 28, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a...

REPCF : 0.0002 (-90.48%)
RP.VN : 0.010 (unch)
RepliCel Announces Dermal Injector Update AccessWire - Wed Oct 27, 2021

Testing progresses to next-phase; results lead to some component upgrades to ensure optimal performance, quality compliance, and commercial-scale production capabilities VANCOUVER, BC / ACCESSWIRE / October...

RP : 88.72 (+0.08%)
REPCF : 0.0002 (-90.48%)
RP.VN : 0.010 (unch)
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy AccessWire - Mon Oct 18, 2021

After several unsuccessful attempts to settle the dispute, RepliCel has filed an arbitration claim seeking Shiseido's full compliance with the agreement or return of the license and all collaboration data...

RP.VN : 0.010 (unch)
REPCF : 0.0002 (-90.48%)

Barchart Exclusives

1 AI Stock to Buy and Hold for Long-Term Growth Barchart - Thu Nov 21, 7:18PM CST
Pure Storage stands out in AI data storage, bolstered by a new partnership with CoreWeave and a solid financial track record, making it an intriguing stock for AI-focused investors Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot